Region-Specific Hepatitis B Virus Genome Exposure from Nucleocapsid Modulated by Capsid Linker Sequence and Inhibitor: Implications for Uncoating.
CCC DNA
antiviral
capsid
cccDNA
covalently closed circular DNA
hepadnavirus
hepatitis B virus
nuclease
nucleocapsid
uncoating
Journal
Journal of virology
ISSN: 1098-5514
Titre abrégé: J Virol
Pays: United States
ID NLM: 0113724
Informations de publication
Date de publication:
27 04 2022
27 04 2022
Historique:
pubmed:
8
4
2022
medline:
30
4
2022
entrez:
7
4
2022
Statut:
ppublish
Résumé
Hepatitis B virus (HBV) contains a partially double-stranded, relaxed circular (RC) DNA genome synthesized within a nucleocapsid (NC) in the host cell cytoplasm. The release of RC DNA from the NC, in an ill-defined process called uncoating, to the nucleus is required for its conversion to the covalently closed circular (CCC) DNA, the viral episome serving as the transcriptional template for all viral RNAs necessary for replication and, thus, essential for establishing and sustaining viral infection. In efforts to better understand uncoating, we analyzed HBV core (HBc) mutants that show various levels of nuclear CCC DNA but little to no cytoplasmic RC DNA. We found that RC DNA could be synthesized by these mutants outside the cell, but in contrast to the wild type (wt), the mutant NCs were unable to protect RC DNA from digestion by the endogenous nuclease(s) in cellular lysates or exogenous DNase. Subcellular fractionation suggested that the major RC DNA-degrading activity was membrane associated. Digestion with sequence-specific and nonspecific DNases revealed the exposure of specific regions of RC DNA from the mutant NC. Similarly, treatment of wt NCs with a core inhibitor known to increase CCC DNA by affecting uncoating also led to region-specific exposure of RC DNA. Furthermore, a subpopulation of untreated wild type (wt) mature NCs showed site-specific exposure of RC DNA as well. Competition between RC DNA degradation and its conversion to CCC DNA during NC uncoating thus likely plays an important role in the establishment and persistence of HBV infection and has implications for the development of capsid-targeted antivirals.
Identifiants
pubmed: 35389266
doi: 10.1128/jvi.00399-22
pmc: PMC9044944
doi:
Substances chimiques
Antiviral Agents
0
Capsid Proteins
0
DNA, Circular
0
DNA, Viral
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0039922Subventions
Organisme : NIAID NIH HHS
ID : R37 AI043453
Pays : United States
Organisme : HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID)
ID : R21-AI1641191
Références
Viruses. 2017 Mar 21;9(3):
pubmed: 28335554
PLoS Pathog. 2017 Sep 25;13(9):e1006658
pubmed: 28945802
J Virol. 2007 May;81(9):4465-72
pubmed: 17314171
Virology. 1999 Jul 5;259(2):342-8
pubmed: 10388659
J Virol. 2015 Mar;89(5):2918-30
pubmed: 25540387
J Virol. 2016 May 27;90(12):5830-5844
pubmed: 27076641
J Virol. 2007 Nov;81(22):12472-84
pubmed: 17804499
Hepatology. 2018 Nov;68(5):1695-1709
pubmed: 29679386
Antiviral Res. 2015 Nov;123:132-7
pubmed: 26408354
Proc Natl Acad Sci U S A. 2005 Jun 21;102(25):9020-5
pubmed: 15951426
J Virol. 2015 Sep;89(17):9021-8
pubmed: 26085156
Biomolecules. 2020 Jul 11;10(7):
pubmed: 32664541
Proc Natl Acad Sci U S A. 2021 Sep 7;118(36):
pubmed: 34465620
EMBO J. 2002 Mar 1;21(5):876-84
pubmed: 11867516
J Virol. 2022 Jan 12;96(1):e0130521
pubmed: 34643434
J Virol. 2013 Nov;87(21):11494-503
pubmed: 23966388
mBio. 2020 Feb 18;11(1):
pubmed: 32071277
Cold Spring Harb Perspect Med. 2015 Jul 01;5(7):a021386
pubmed: 26134841
J Virol. 1995 Oct;69(10):6158-69
pubmed: 7666518
Cell. 1986 Nov 7;47(3):451-60
pubmed: 3768961
Biomedicines. 2021 Oct 29;9(11):
pubmed: 34829806
J Virol. 2020 Dec 9;95(1):
pubmed: 33055252
J Virol. 2007 Feb;81(4):1641-9
pubmed: 17135319
J Virol. 2007 Jun;81(12):6164-74
pubmed: 17409153
J Virol. 2015 Mar;89(6):3275-84
pubmed: 25568211
J Virol. 2018 Nov 12;92(23):
pubmed: 30232184
PLoS Pathog. 2010 Sep 02;6(9):e1001082
pubmed: 20824087
J Virol. 2019 Sep 30;93(20):
pubmed: 31375584
Elife. 2012 Nov 13;1:e00049
pubmed: 23150796
Proc Natl Acad Sci U S A. 2010 Mar 2;107(9):4383-8
pubmed: 20142477
Nature. 2017 Sep 21;549(7672):394-398
pubmed: 28902841
J Virol. 2005 Aug;79(15):9369-80
pubmed: 16014900
Virology. 2012 Aug 15;430(1):20-9
pubmed: 22595445
PLoS Pathog. 2020 Jul 23;16(7):e1008669
pubmed: 32702076
Antimicrob Agents Chemother. 1997 Aug;41(8):1715-20
pubmed: 9257747
J Virol. 2017 Apr 13;91(9):
pubmed: 28228589
J Virol. 2017 Aug 10;91(17):
pubmed: 28637752
J Virol. 1998 Nov;72(11):9116-20
pubmed: 9765457
Gastroenterology. 2019 Jan;156(2):338-354
pubmed: 30243619
Antiviral Res. 2020 Oct;182:104917
pubmed: 32818519
PLoS Pathog. 2015 Apr 22;11(4):e1004840
pubmed: 25902143
J Virol. 2015 Oct 21;90(1):486-96
pubmed: 26491170
J Virol. 2021 May 24;95(12):
pubmed: 33789995
J Virol. 2015 Oct;89(19):10064-72
pubmed: 26202253
PLoS Pathog. 2018 May 21;14(5):e1007085
pubmed: 29782550
PLoS Pathog. 2020 Mar 30;16(3):e1008459
pubmed: 32226051
PLoS Pathog. 2021 Jan 25;17(1):e1009230
pubmed: 33493210
Emerg Microbes Infect. 2021 Dec;10(1):852-864
pubmed: 33870849
J Virol. 2016 Apr 14;90(9):4827-4831
pubmed: 26865711
J Virol. 2018 Mar 14;92(7):
pubmed: 29367244
Cells. 2020 Nov 06;9(11):
pubmed: 33172220
J Virol. 2011 Jul;85(13):6319-33
pubmed: 21507968
PLoS Pathog. 2020 Oct 20;16(10):e1008945
pubmed: 33079954
J Virol. 2012 Nov;86(22):12237-50
pubmed: 22951823
PLoS One. 2015 Jun 16;10(6):e0128401
pubmed: 26079492
PLoS One. 2011 Feb 15;6(2):e17202
pubmed: 21358805